Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Rudin

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
Lupus Science & Medicine|October 16, 2023
B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosusAnna Hedenstedt, Sarah Reid, Ahmed Sayadi, et al.
Arthritis Research & Therapy|March 5, 2024
Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritisJianyang Liu, Helena Idborg, Marina Korotkova, et al.
Journal of Internal Medicine|November 7, 2025
Genetic risk factors and clinical manifestations of systemic lupus erythematosus: Large-scale analysis of genetic predisposition and disease subtypesSarah Reid, Johanna K Sandling, Pascal Pucholt, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 31, 2023
Autoantibodies to Disease-Related Proteins in Joints as Novel Biomarkers for the Diagnosis of Rheumatoid ArthritisErik Lönnblom, Monica Leu Agelii, Outi Sareila, et al.
Clinical and Experimental Rheumatology|November 19, 2021
Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritisJonathan Aldridge, Anna-Carin Lundell, Kerstin Andersson, et al.
ACR Open Rheumatology|August 29, 2025
Association of Soluble Immune Checkpoint Molecules PD1 and 4-1BB With CTLA-4Ig Treatment Response in Early Rheumatoid ArthritisTilia Selldén, Kristina Lend, Jon Lampa, et al.
RMD Open|June 6, 2025
Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trialKristina Lend, Jos Wr Twisk, Nupur Kumar, et al.
ACR Open Rheumatology|November 4, 2024
Circulating Adipokines and Response to Treatment in Patients With Early Rheumatoid ArthritisGeorgios K Vasileiadis, Yuan Zhang, Tahzeeb Fatima, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 17, 2023
Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled TrialKristina Lend, Frieda A Koopman, Jon Lampa, et al.
Arthritis Research & Therapy|July 14, 2021
Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trialMarit Stockfelt, Anna-Carin Lundell, Merete Lund Hetland, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
Lupus Science & Medicine|October 16, 2023
B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosusAnna Hedenstedt, Sarah Reid, Ahmed Sayadi, et al.
Arthritis Research & Therapy|March 5, 2024
Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritisJianyang Liu, Helena Idborg, Marina Korotkova, et al.
Journal of Internal Medicine|November 7, 2025
Genetic risk factors and clinical manifestations of systemic lupus erythematosus: Large-scale analysis of genetic predisposition and disease subtypesSarah Reid, Johanna K Sandling, Pascal Pucholt, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 31, 2023
Autoantibodies to Disease-Related Proteins in Joints as Novel Biomarkers for the Diagnosis of Rheumatoid ArthritisErik Lönnblom, Monica Leu Agelii, Outi Sareila, et al.
Clinical and Experimental Rheumatology|November 19, 2021
Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritisJonathan Aldridge, Anna-Carin Lundell, Kerstin Andersson, et al.
ACR Open Rheumatology|August 29, 2025
Association of Soluble Immune Checkpoint Molecules PD1 and 4-1BB With CTLA-4Ig Treatment Response in Early Rheumatoid ArthritisTilia Selldén, Kristina Lend, Jon Lampa, et al.
RMD Open|June 6, 2025
Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trialKristina Lend, Jos Wr Twisk, Nupur Kumar, et al.
ACR Open Rheumatology|November 4, 2024
Circulating Adipokines and Response to Treatment in Patients With Early Rheumatoid ArthritisGeorgios K Vasileiadis, Yuan Zhang, Tahzeeb Fatima, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 17, 2023
Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled TrialKristina Lend, Frieda A Koopman, Jon Lampa, et al.
Arthritis Research & Therapy|July 14, 2021
Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trialMarit Stockfelt, Anna-Carin Lundell, Merete Lund Hetland, et al.
Pageof 10